As clinicians increasingly encounter patients with IBD as well as obesity, diabetes, or metabolic liver disease, there is a clear need to synthesize what is known about safety, metabolic effects, and IBD-specific outcomes to support evidence-informed clinical decision-making, explains senior investigator and study author Jolle St-Pierre, MD, PhD, FRCPC, a clinical assistant professor in the Division of Gastroenterology and Hepatology at the University of Calgary, Canada, in an email to Gastro Today
The metabolic and weight loss benefits of Ozempic are meaningful
Studies show that patients can attain an average reduction of approximately 0.5 pounds weekly, with many shedding up to 20% of their initial mass over time
One document rarely proves everything